Shots:

• The P-III EAGLE study involved assessing of Imfinzi as monothx or Imfinzi + tremelimumab vs SoC CT in patients with recurrent or metastatic HNSCC who experienced progression following Pt-based CT- at 169 centers across 24 countries
• The P-III EAGLE study results demonstrated that it didn’t met 1EPs as OS and has shown safety and well-tolerated signs in patients 
• Imfinzi (durvalumab) is a mAb- binds with PD-L1 and blocks its interaction with PD-1 and CD80- is approved in 40 countries including the US- EU and Japan for Stage III NSCLC. Tremelimumab is a mAb- used for targeting the activity of cytotoxic T-lymphocyte-associated protein 4 (CTLA-4)

Ref: AstraZeneca | Image: AstraZeneca